SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalGeron Corp.


Previous 10 Next 10 
From: tktrimbath6/30/2018 6:42:45 PM
   of 3521
 
My mid-year synopsis of GERN - 2018

INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.

Geron

GERN (market cap is $0.594B was $0.287B)

Geron is a leading edge biotechnology firm developing a cancer vaccine treatment based on managing telomerase. Their most advanced treatment is addressing blood disorders. As with other cancer vaccines, the first treatment approved may be sufficient for profitability, but the upside is amplified if the same technology can be applied to other cancers. Currently, Geron is in phase 2 / 3 clinical trials. If successful, the treatment must still be approved by the FDA before becoming publicly available. Each positive step closer decreases the risk to the company and the risk discount to the stock.

Pardon the copy and paste from another, similar, and associated company (Asterias, AST), but the same statements apply.

“A major caution with innovative biotechnology companies and their treatments is that the FDA is not as innovative in its approval process. … Unless the FDA decides to accelerate the process on compassionate grounds, public treatments and subsequent profits are many years away.”

DISCLOSURE LTBH since 1999 and continuing to hold. I might consider buying more, but will probably wait for substantial, quantitative results are made public - which would spark a spike that might price me out of the sale. Stay tuned.

(I've also collected links to the other discussion boards and my other stocks over on my blog trimbathcreative.wordpress.com

Share RecommendKeepReplyMark as Last Read


From: Savant7/9/2018 1:17:41 AM
   of 3521
 
RT...
trendintech.com

Share RecommendKeepReplyMark as Last Read


From: Savant8/24/2018 12:26:12 PM
   of 3521
 
Geron up 42% on expectations of J&J continuing with imetelstat
Aug. 24, 2018 9:57 AM ET|About: Geron Corporation (GERN)|By: Douglas W. House, SA News Editor

Geron ( GERN +42.2%) is up on double normal volume in apparent response to a job posting for a pricing manager whose duties will include a setting a pricing approach for imetelstat, implying that its Janssen unit will continue development.

Janssen is expected to notify Geron on its decision this quarter.

Share RecommendKeepReplyMark as Last Read


From: tktrimbath10/2/2018 5:49:45 PM
1 Recommendation   of 3521
 
My Almost 20 Year Perspective on GERN

Cross-posted on Twitter (@tetrimbath) and Investor Village.

It takes more than one perspective to truly see a picture. Here's one example from my investing portfolio.
"After last week’s drop and today’s rise, the stock sits at $1.71, a more than 10% raise in less than a year."
"Time is more valuable than money, and I feel its loss just as much."

trimbathcreative.wordpress.com


Share RecommendKeepReplyMark as Last Read


From: tktrimbath12/31/2018 4:40:27 PM
   of 3521
 
My end of year review of GERN

INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.

Geron
GERN (market cap is $0.186B was $0.594B)
Geron is a leading edge biotech company developing treatments for cancer through the management of telomeres, the molecules that manage cell growth and death. Treatments are in clinical trials, which means they are beyond simple lab tests, but it also means they have yet to apply for or achieve FDA approval. A classic risk/reward trade because the risks of getting approval for innovative treatments is difficult, and the rewards are great because of a great unmet need with very little competition.

They are continuing through clinical trials, but have not produced results that have enthused the investing community. The company has also been shedding intellectual assets for years (see AST), and has had to rely on partner companies.
I’ll continue to hold. I’ve sold shares to buy into other opportunities, but want to hold onto a core, just in case.

DISCLOSURE LTBH since 1999 and continuing to hold. I might consider buying more, but will probably wait for substantial, quantitative results are made public - which would spark a spike that might price me out of the sale. Stay tuned.
(I've also collected links to the other discussion boards and my other stocks over on my blog trimbathcreative.wordpress.com

Share RecommendKeepReplyMark as Last Read


From: cycleupcycledown6/17/2019 12:23:12 PM
   of 3521
 
Loaded up $1.50...for future bragging rights....thinking approval or another partner or both.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: cycleupcycledown who wrote (3498)6/18/2019 10:30:30 AM
From: tktrimbath
   of 3521
 
Any news that inspired the action, or is it intuition?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: tktrimbath who wrote (3499)6/18/2019 10:32:22 AM
From: cycleupcycledown
   of 3521
 
Intuition, I hope they get another partner.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: cycleupcycledown who wrote (3500)6/18/2019 1:04:00 PM
From: cycleupcycledown
   of 3521
 
Some folks over on geron twits think confidental talks are underway....I'm running wid it.

Share RecommendKeepReplyMark as Last Read


From: cycleupcycledown6/27/2019 6:27:00 PM
   of 3521
 
Kol report had a page with the flags of the researchers countries....global interest

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10